Astrocytoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) HC (1) | IDH1 p.R132C | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH1 p.R132G | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH1 p.R132H | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH1 p.R132L | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH1 p.R132S | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172K | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172M | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172G | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172S | Astrocytoma | Vorasidenib | |
| FDA (1) HC (1) | IDH2 p.R172W | Astrocytoma | Vorasidenib |